New survey by Phenomix Sciences: 57% of obesity patients unaware of non-GLP-1 options like Qsymia, but after education, 68% shifted views—25% more open to alternatives.
#ObesityCare #GLP1 #PatientEducation #PersonalizedMedicine #News
Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.
Novo Nordisk’s new Wegovy subscription program shows how serious the company is about direct-to-consumer and cash-pay obesity care, and how ready it is to compete with Lilly.
jcst2d.com/index.php/ne...
#Wegovy #NovoNordisk #ObesityCare
Yesterday in Montreal, @obesitycanada.bsky.social an convened patient advocates from all over the world to develop a patient charter for #ObesityCare. Here's why that's so important.
conscienhealth.org/2026/03/26/w...
Eli Lilly Logo
Retatrutide’s first Phase 3 diabetes results are drawing attention for strong A1C and weight loss, plus what clinicians see as real relevance for type 2 diabetes care.
jcst2d.com/index.php/ne...
#Type2Diabetes #Retatrutide #ObesityCare
Wegovy HD 7.2 mg Pen
FDA approves Wegovy HD, adding semaglutide 7.2 mg for obesity. The key question is what it means in practice for people who respond to 2.4 mg but plateau.
jcst2d.com/index.php/ne...
#ObesityCare #Semaglutide #WegovyHD
Zealand Pharma Logo
Phase 2 results for Zealand Pharma’s petrelintide show meaningful weight loss with strong tolerability, highlighting treatment persistence as a key factor in obesity care.
jcst2d.com/index.php/ne...
#Petrelintide #ObesityCare #ClinicalTrials #MetabolicHealth
Clinical trial results matter most when they translate into sustainable health improvements.
REDEFINE-4 shows obesity care is moving toward more options, not one winner. It isn't about which drug "won." It’s about how treatment is evolving and what that means for patients.
jcst2d.com/index.php/ne...
#ObesityCare #ClinicalTrials #PatientCenteredCare
GLP-1 isn’t a miracle.
It’s a metabolic tool.
Without muscle preservation and long-term strategy, weight loss rebounds.
Obesity is metabolic disease — not a character flaw.
#GLP1 #MetabolicDisease #ObesityCare
As cheaper Wegovy options surface – from discounts to compounded pills – FDA warnings spotlight safety, trust and what longevity costs.
vist.ly/4rdf2
#longevity #Wegovy #ObesityCare #MetabolicHealth #GLP1 #DrugSafety #FDA #HealthcarePolicy
In this CME, explore guideline updates, shared decision-making tools, and approaches that reduce bias while building effective obesity management plans.
▶️ https://wb.md/4qxIhzW
#ObesityCare #PrimaryCare
Milan-based healthtech startup closes $2.2 million (€2 million) pre-seed round to build a preventive way of managing obesity.
longevity.technology/news/robin-h...
#longevity #ObesityCare #PreventiveHealth #HealthTech #MetabolicHealth #WeightLoss #StartupFunding #VentureCapital
Health Canada approves Rybelsus, the first oral GLP-1 pill to lower cardiovascular risk in adults with Type 2 diabetes.
longevity.technology/news/canada-...
#longevity #GLP1 #diabetes #cardiometabolic #hearthealth #metabolichealth #obesitycare #digitalhealth #biotechnews
"You deserve a health team that truly cares."
At Decatur Health and Wellness, we specialize in lasting weight loss, obesity care, primary care, and hormone replacement. Start your transformation today!
🔗 Link in bio to book your appointment!
#WeightLoss #ObesityCare #HealthAndWellness
The onslaught of marketing for #telehealth #WeightLoss and #ObesityCare is daunting. Here are some thoughts about sorting through it all.
Thx to Katherine Saunders MD for insight.
conscienhealth.org/2026/01/09/t...
Image of 1.5 mg starter dose of Wegovy® pill. Courtesy of Novo Nordisk.
Wegovy’s new oral GLP-1 pill is now available in the U.S., offering a daily option with strong results but strict dosing rules. Here’s what to know about real-world use and coverage.
jcst2d.com/index.php/ne...
#Wegovy #GLP1 #ObesityCare #WeightManagement #DiabetesCare
New year weight loss plans collide with surge in scams, prompting warnings for consumer vigilance as injectable treatments grow in popularity.
longevity.technology/news/pharmac...
#longevity #GLP1 #weightloss #pharmacy #drugSafety #metabolicHealth #obesityCare
2026 could redefine obesity treatment, as pills, pricing shifts and more powerful injections reshape a scarce and expensive market.
longevity.technology/news/pills-p...
#longevity #obesitycare #weightlossdrugs #biopharma #healthpolicy #2026outlook
Intragastric Balloon Market expands with demand for non-surgical weight loss solutions. www.marketresearchfuture.com/reports/intr... #ObesityCare
There's news today on access to obesity care that gives us cause to hope for equitable #access to #ObesityCare for all – free from stigma and blame.
conscienhealth.org/2025/12/a-ch...
Novo Nordisk flags. Courtesy of Novo Nordisk.
FDA approves first oral GLP-1 for chronic weight management, reinforcing obesity as chronic disease and shifting care toward long-term treatment.
jcst2d.com/index.php/ne...
#ObesityCare #GLP1 #WeightManagement #FDAApproval #MetabolicHealth
Toplines from the @elilillyandcompany.bsky.social oral GLP-1 tablet are making us think #maintain might be the magic word in #ObesityCare next year. Losing weight is (relatively) easy. Keeping it off is where the challenge lies.
HT: @michaelalbertmd.bsky.social
conscienhealth.org/2025/12/will...
At NIH last week, a symposium on sustainable #ObesityCare and the gaps in research to support it really laid out the most pressing questions for moving beyond present simplistic #WeightLoss thinking.
conscienhealth.org/2025/12/movi...
hands
In this CME, learn practical strategies and the latest evidence to strengthen care for patients living with obesity in primary care.
▶️ ms.spr.ly/63326tjS10
#ObesityCare #PrimaryCare
New from PSW: ForwardHealth Anti-Obesity Drug Coverage Toolkit
A practical guide to help pharmacy teams navigate WI Medicaid & SeniorCare coverage for anti-obesity meds and streamline PA requests.
Learn more: www.pswi.org/GLP-Toolkit
#ObesityCare #WeightManagement #Medicaid
Novo Nordisk headquarters. Courtesy of News Øresund - Johan Wessman - Licensed under CC BY 3.0. Photo link: https://www.flickr.com/photos/newsoresund/29190030262.
Novo Nordisk files NDA for a higher 7.2 mg dose of Wegovy, supported by STEP UP trial results and an accelerated FDA review.
jcst2d.com/index.php/ne...
#Wegovy #Semaglutide #ObesityCare #GLP1 #ClinicalTrials
Martin Holst Lange, MD, PhD. Image courtesy of Novo Nordisk.
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes, with meaningful HbA1c and weight reductions. EVOKE findings add valuable insight for Alzheimer’s research.
jcst2d.com/index.php/ne...
#Diabetes #ObesityCare #GLP1 #Amycretin #ClinicalTrials
How common are eating disorders in adults seeking obesity treatment? 🌍
Most research focuses on binge eating, but what about everything else? This systematic review brings together data from 94,000 adults to map the full picture.
🧵 THREAD
#EatingDisorders #ObesityCare #MentalHealth
We’re live at the PCDO Conference in Birmingham!
Come and say hi👋 to the LDC representatives today in the exhibition space to explore our work in diabetes and obesity care.
Details below⬇️
#PCDOConference #Diabetes #ObesityCare
Eli Lilly has enlisted the aid of Tan France of US makeover show Queer Eye to change the narrative about #obesity in a new campaign. #ObesityCare #PatientCentricity #InclusiveHealthcare #PublicHealthCampaign
pharmaphorum.com/news/queer-e...
🎯 "The Latino community has been directly targeted — and we need to speak up about it."
🗣️ Watch this powerful clip from our latest NMQF webinar — and catch the full panel here: youtu.be/KtH22wzijcs
#HealthEquity #ObesityCare #LatinoHealth #LULAC #NMA #NMQF #FYHNews #DiabetesAwareness
